Raymond James & Associates’s Legend Biotech LEGN Stock Holding History

Raymond James & Associates’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$292K	Buy	+5,986	New	+$319K	﹤0.01%	3423

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Raymond James & Associates's LEGN Position: Q3 2024 in Review

Raymond James & Associates opened a new position in Legend Biotech (LEGN) in Q3 2024: 5,986 shares worth $292K. The stake represents ﹤0.01% of the portfolio and ranks #3423 among its holdings.

208 funds tracked by Wall St. Rank hold LEGN as of Q3 2024.

Raymond James & Associates held 5,986 shares of Legend Biotech worth $292K as of Q3 2024.
Legend Biotech was a new Raymond James & Associates position in Q3 2024.
Legend Biotech made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3423 holding.
208 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.